Home/Filings/4/0000899243-22-031347
4//SEC Filing

Biehl James 4

Accession 0000899243-22-031347

CIK 0001537917other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 6:00 PM ET

Size

26.6 KB

Accession

0000899243-22-031347

Insider Transaction Report

Form 4
Period: 2022-09-16
Biehl James
Director
Transactions
  • Disposition to Issuer

    Common Stock

    2022-09-16105,0000 total
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-16500,0000 total
    Exercise: $2.42Exp: 2028-09-08Common Stock (500,000 underlying)
  • Disposition to Issuer

    Common Stock

    2022-09-161500 total(indirect: See Footnote)
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-16253,2000 total
    Exercise: $1.56Exp: 2029-05-02Common Stock (253,200 underlying)
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-16500,0000 total
    Exercise: $1.43Exp: 2031-06-13Common Stock (500,000 underlying)
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-1612,5000 total
    Exercise: $2.95Exp: 2027-03-28Common Stock (12,500 underlying)
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-16360,0000 total
    Exercise: $1.39Exp: 2030-05-06Common Stock (360,000 underlying)
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-1675,0000 total
    Exercise: $2.90Exp: 2028-05-24Common Stock (75,000 underlying)
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-16482,2000 total
    Exercise: $0.32Exp: 2032-04-21Common Stock (482,200 underlying)
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-1612,5000 total
    Exercise: $2.95Exp: 2027-03-28Common Stock (12,500 underlying)
Footnotes (11)
  • [F1]Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,601 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
  • [F10]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 547 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.
  • [F11]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
  • [F2]Disposed of pursuant to the merger agreement between the issuer and Syros in exchange for 6 shares of Syros common stock after giving effect to the Reverse Split, with cash paid in lieu of fractional shares.
  • [F3]150 shares are owned by Mr. Biehl's spouse.
  • [F4]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $55.23 per share, after giving effect to the Reverse Split.
  • [F5]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 11,095 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.
  • [F6]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 15,775 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.
  • [F7]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
  • [F8]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,130 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.
  • [F9]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 547 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.

Issuer

TYME TECHNOLOGIES, INC.

CIK 0001537917

Entity typeother

Related Parties

1
  • filerCIK 0001710484

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:00 PM ET
Size
26.6 KB